18 / 26
Page 72
Journal of Aging Science | ISSN: 2329-8847 | Volume 5
July 18-19, 2018 | Atlanta, USA
Aging & Gerontology
3
rd
International Conference on
Factors associated with ketamine use in pancreatic cancer patient in a single hospice center
Kyung Min Kwon
St.Mary's Hospital, Korea
Purpose:
Up to 90% of pancreatic cancer patient suffer from neuropathic pain. In palliative care setting, pain control in pancreatic
cancer patient is one of the major goals. Ketamine is a NMDA receptor antagonist effective in neuropathic pain. Also there have been
studies about opioid sparing effect of ketamine. This study was held in palliative care unit among pancreatic cancer patients to find
out the factors related to ketamine use and the opioid sparing effect.
Methods:
Medical records of pancreatic cancer patients admitted to St.Mary’s hospital palliative care unit from 2013.1 to 2014.12
were reviewed. Patients were divided in to 2 categories according to ketamine use. Also opioid use before and after ketamine use was
compared in ketamine group.
Results:
Compared to non ketamine use group, patients in ketamine group required higher dose of opioid. Total opioid dose, daily
opioid dose, number of daily rescue medication, daily average rescue dose were statistically significantly higher in ketamine group.
Opioid requirement was increased after ketamine administration.
Conclusion:
In this study, ketamine group required more opioid. Ketamine is frequently considered in patients with severe pain,
requiring high amount of opioid. Also ketamine did not have a opioid sparing effect. Future studies about palliative use of ketamine
in larger number of patients are required.
kmkwins@naver.comJ Aging Sci 2018, Volume 5
DOI: 10.4172/2329-8847-C1-006